Patents by Inventor Marek Zatloukal

Marek Zatloukal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12378247
    Abstract: A para-topolin mesylate salt and its crystalline form is disclosed. Cosmetic and therapeutic applications, and compositions containing this compound, are also disclosed. Mesylate salt of para-topolin has a wide range of biological activities, including antioxidative, anti-inflammatory, anti-senescent and anti-aging while showing low toxicity and excellent solubility.
    Type: Grant
    Filed: August 22, 2020
    Date of Patent: August 5, 2025
    Assignee: USTAV EXPERIMENTALNI BOTANIKY AV CR, V. V. I.
    Inventors: Lucie Plihalova, Marek Zatloukal, Karel Dolezal, Miroslav Strnad, Jan Walla, Jiri Voller
  • Patent number: 12319694
    Abstract: Heterocyclic nitrogen-containing purine derivatives and their use in the medicinal applications and compositions containing these derivatives is disclosed. A new generation of compounds possessing selective antineurodegenerative properties on neuronal cells and tissues and that can be particularly used in the treatment and prophylaxis of neurodegenerative disease, particularly in the treatment and prophylaxis of Parkinson's disease is also disclosed.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: June 3, 2025
    Assignees: UNIVERZITA PALACKEHO, FAKULTNI NEMOCNICE OLOMOUC
    Inventors: Gabriel Gonzales, Vaclav Mik, Noemi Bucharova, Jiri Gruz, Petr Kanovsky, Miroslav Strnad, Marek Zatloukal
  • Patent number: 11643413
    Abstract: The invention relates to N2,N6-disubstituted-9-(2-oxacycloalkyl)-9H-purine-2, 6-diamine derivatives and their use as drugs and cosmetics. The compounds of the present invention exhibit a number of biological activities associated with oxidative stress inhibition, especially anti-aging, anti-inflammatory and anti-neurodegenerative biological activities. The invention also relates to cosmetic and pharmaceutical compositions containing such derivatives as active agents.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 9, 2023
    Assignee: UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Jana Bibova, Vaclav Mik, Marek Zatloukal, Lucie Plihalova, Jiri Gruz, Lukas Spichal, Karel Dolezal, Miroslav Strnad
  • Patent number: 10662194
    Abstract: The invention relates to substituted 6-anilino-9-heterocyclylpurine derivatives of formula I wherein R denotes one to five substituents independently selected from the group hydrogen, halogen, hydroxy, amino, alkyloxy and alkyl group, R2 is selected from the group comprising amino, halogen, hydroxy, thio, and alkylthio group, Cyc is five- or six-membered heterocyclic ring containing one oxygen atom. The derivatives are useful for inhibition of plant stress.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: May 26, 2020
    Assignee: UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Marek Zatloukal, Lucie Plihalova, Jana Klaskova, Lukas Spichal, Radoslav Koprna, Karel Dolezal, Miroslav Strnad
  • Patent number: 10550144
    Abstract: 6-aryl-9-glycosidpurines of general formula I and pharmaceutically acceptable salts thereof with alkali metals, ammonia, amines, or addition salts with acids, wherein Gly represents ?-D-arabinofuranosyl or ?-D-2?-deoxyribofuranosyl, Ar represents benzyl or furfuryl, each of which can be unsubstituted or substituted by one or more, preferably one to three, substituents selected from the group comprising hydroxyl, alkyl, halogen, alkoxy, amino, mercapto, carboxyl, cyano, amido, sulfo, sulfamido, acyl, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, trifluoromethyl, trifluoromethoxy, for use for regulation, in particular inhibition, of aging in plants in vivo or plant cells in vitro, and for regulation of growth and development of plants in vivo, plant tissues, plant organs and plant cells in vitro.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: February 4, 2020
    Assignee: UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Karel Dolezal, Lucie Plihalova, Hana Vylicilova, Marek Zatloukal, Ondrej Plihal, Jiri Voller, Miroslav Strnad, Johannes Van Staden, Ponnusamy Baskaran, Aloka Kumari, Adeyemi Oladapo Aremu
  • Patent number: 10100077
    Abstract: 6-aryl-9-glycosidpurines of general formula I and pharmaceutically acceptable salts thereof with alkali metals, ammonia, amines, or addition salts with acids, wherein Gly represents ?-D-arabinofuranosyl or ?-D-2?-deoxyribofuranosyl, Ar represents benzyl or furfuryl, each of which can be unsubstituted or substituted by one or more, preferably one to three, substituents selected from the group comprising hydroxyl, alkyl, halogen, alkoxy, amino, mercapto, carboxyl, cyano, amido, sulfo, sulfamido, acyl, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, trifluoromethyl, trifluoromethoxy, for use as antisenescent and UV protective compounds in animals.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: October 16, 2018
    Assignee: UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Karel Dolezal, Lucie Plihalova, Hana Vylicilova, Marek Zatloukal, Ondrej Plihal, Jiri Voller, Miroslav Strnad, Magdalena Bryksova, Jitka Vostalova, Alena Rajnochova Svobodova, Jitka Ulrichova, Lukas Spichal
  • Patent number: 10093675
    Abstract: 6,8-Disubstituted-9-(heterocyclyl)purines for use in pharmaceutical and cosmetic compositions and applications are provided. These 6,8-disubstituted-9-(heterocyclyl)purines have a wide range of biological activities, including for example antioxidant, anti-inflammatory, anti-senescent, anti-aging, as well as well as other activities which are especially useful in pharmaceutical and cosmetic applications. Compositions may include additional excipients and auxiliary substances. Methods of treatment of animals, mammals, plants, cells, yeast, and cells in tissue culture are also disclosed.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: October 9, 2018
    Assignees: USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Lenka Zahajska, Jaroslav Nisler, Alena Kadlecova, Marek Zatloukal, Jiri Gruz, Jiri Voller, Karel Dolezal, Miroslav Strnad
  • Patent number: 9993002
    Abstract: Substituted 1,2,3-thiadiazol-5yl-urea derivatives, their use as anti-senescence and anti-stress factors of plant cells, organs and the whole plant, and preparations containing these derivatives.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: June 12, 2018
    Assignees: USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Jaroslav Nisler, Marek Zatloukal, Lukas Spichal, Radoslav Koprna, Karel Dolezal, Miroslav Strnad
  • Patent number: 9073961
    Abstract: The invention relates to substitution derivatives of N6-benzyladenosine-5?-monophosphate of the general formula I, wherein (R)n represents 1 to 4 substituents (n is in the range 1-4), which can be the same or different, and R is selected from the group comprising C1 to C8 alkyl, C1 to C8 alkoxy, amino, halogen, hydroxy, mercapto and nitro groups, and the pharmaceutically acceptable salts thereof. This invention also relates to methods of their preparation, their use as medicaments and in other biotechnological applications, and a therapeutic composition containing these derivatives.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: July 7, 2015
    Assignees: UNIVERZITA PALACKEHO V OLOMOUCI, BIOAPEX, S.R.O.
    Inventors: Marek Zatloukal, Karel Dolezal, Jiri Voller, Lukas Spichal, Miroslav Strnad
  • Patent number: 9023857
    Abstract: The invention relates to new substituted 6-(2-aminobenzylamino)purines, represented by the general formula I, which can be used in CDK inhibition, in particular, in the treatment of viral infections and diseases involving cell proliferation. The invention further includes pharmaceutical preparations containing substituted 6-(2-aminobenzylamino)purines.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: May 5, 2015
    Assignee: Univerzita Palackeho V Olomouci
    Inventors: Libor Havlicek, Vladimir Krystof, Marek Zatloukal, Karel Dolezal, Miroslav Strnad, Borivoj Vojtesek
  • Patent number: 8575182
    Abstract: Certain 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts of the general formula are provided wherein R6 and R9 are as defined in the specification. These 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are useful in compositions for treating mammalian cells, and especially human skin cells, in order to ameliorate the adverse effects of aging, treat skin disease states, treat immunological responses resulting from or associated with inflammation, and the like.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: November 5, 2013
    Assignee: Institute of Experimental Botany, Academy of Sciences of the Czeck Republic
    Inventors: Lucie Szucova, Marek Zatloukal, Lukas Spichal, Jiri Voller, Karel Dolezal, Miroslav Strnad, Frank J. Massino
  • Patent number: 8552013
    Abstract: Novel heterocyclic derivatives based on N6-substituted adenine, having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells and methods of their preparation. Included are also pharmaceutical compositions, cosmetic preparations and growth regulators, which contain these derivatives as active compound and the use of these derivatives for the preparation of drugs, cosmetic preparations, in biotechnological processes, in cosmetics and in agriculture.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: October 8, 2013
    Assignee: USTAV Experimentalni Botaniky Akademie Ved Ceske Republiky
    Inventors: Igor Popa, Jan Holub, René Lenobel, Stefaan Werbrouck, Karel Dolezal, Miroslav Strnad, Marek Zatloukal, Frank J. Massino
  • Patent number: 8492391
    Abstract: The invention relates to substituted 6-(2-hydroxybenzylamino)purines of general formula I, to their activity as cyclin-dependent kinases 2, 5, 7 and 9 inhibitors and to their use as medicaments, particularly in the treatment of disorders involving cell proliferation or inflammation. The invention further includes pharmaceutical compositions containing the substituted 6-(2-hydroxybenzylamino)purines.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: July 23, 2013
    Assignees: Univerzita Palackeho V Olomouci, Biopatterns, S.R.O.
    Inventors: Marek Zatloukal, Vladimir Krystof, Libor Havlicek, Igor Popa, Karel Dolezal, Miroslav Strnad, Radek Jorda
  • Publication number: 20130040908
    Abstract: Substitution derivatives of N6-benzyladenosine-5?-monophosphate of the general formula I, wherein (R)n represents 1 to 4 substituents (n is in the range 1-4), which can be the same or different, and R is selected from the group comprising C1 to C8 alkyl, C1 to C8 alkoxy, amino, halogen, hydroxy, mercapto and nitro groups, and the pharmaceutically acceptable salts thereof. A Method for their preparation, their use as medicaments and in other applications, and a therapeutic composition containing these derivatives is also disclosed.
    Type: Application
    Filed: April 28, 2011
    Publication date: February 14, 2013
    Applicants: BIOAPEX, S.R.O., UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Marek Zatloukal, Karel Dolezal, Jiri Voller, Lukas Spichal, Miroslav Strnad
  • Patent number: 8222260
    Abstract: The invention relates to substituted 6-anilinopurine derivatives of the general formula I, wherein R denotes one to five substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, alkyloxy and alkyl group, and R2 denotes amino, halogen, nitro, thio, alkylthio or alkyl group for use as inhibitors of cytokinin oxidase/dehydrogenase. The invention also relates to the compositions containing these derivatives.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: July 17, 2012
    Assignees: Univerzita Palackego V Olomouci, Freie Universitat Berlin
    Inventors: Lukas Spichal, Marketa Gemrotova, Marek Zatloukal, Jitka Frebortova, Petr Galuszka, Tomas Werner, Thomas Schmulling, Karel Dolezal, Miroslav Strnad
  • Publication number: 20120070512
    Abstract: The invention relates to substituted 6-(2-hydroxybenzylamino)purines of general formula I, to their activity as cyclin-dependent kinases 2, 5, 7 and 9 inhibitors and to their use as medicaments, particularly in the treatment of disorders involving cell proliferation or inflammation. The invention further includes pharmaceutical compositions containing the substituted 6-(2-hydroxybenzylamino)purines.
    Type: Application
    Filed: June 2, 2010
    Publication date: March 22, 2012
    Inventors: Marek Zatloukal, Vladimir Krystof, Libor Havlicek, Igor Popa, Karel Dolezal, Miroslav Strnad, Radek Jorda
  • Publication number: 20120071433
    Abstract: The invention relates to 2-substituted-6-(substituted benzylamino)purine riboside derivatives of the general formula I. These compounds possess antiapoptotic, anti-inflammatory and differentiating activities. The invention relates also to the compositions, which contain these derivatives as active ingredients.
    Type: Application
    Filed: May 12, 2010
    Publication date: March 22, 2012
    Inventors: Lucie Szucova, Viadimir Krystof, Marek Zatloukal, Karel Dolezal, Miroslav Strnad, Lukas Spichal
  • Patent number: 8119614
    Abstract: The invention concerns novel substitution derivatives of N6-benzyladenosine having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells. This invention also relates to the methods of preparation of these N6-benzyladenosine derivatives and their use as drugs, cosmetic preparations and growth regulators comprising these derivatives as active compound and use of these derivatives for preparation of pharmaceutical compositions, in biotechnological processes, in cosmetics and in agriculture.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: February 21, 2012
    Assignee: Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky
    Inventors: Karel Dolezal, Igor Popa, Marek Zatloukal, René Lenobel, Dana Hradecká, Borivoj Vojtesek, Stjepan Uldrijan, Petr Mlejnek, Stefaan Werbrouck, Miroslav Strnad
  • Publication number: 20110287111
    Abstract: The invention relates to new substituted 6-(2-aminobenzylamino)purines, represented by the general formula I, which can be used in CDK inhibition, in particular, in the treatment of viral infections and diseases involving cell proliferation. The invention further includes pharmaceutical preparations containing substituted 6-(2-aminobenzylamino)purines.
    Type: Application
    Filed: January 22, 2010
    Publication date: November 24, 2011
    Inventors: Libor Havlicek, Vladimir Krystof, Marek Zatloukal, Karel Dolezal, Miroslav Strnad, Borivoj Vojtesek
  • Publication number: 20110230503
    Abstract: Certain 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are provided. These 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are useful in compositions for treating mammalian cells, and especially human skin cells, in order to ameliorate the adverse effects of aging, treat skin disease states, treat immunological responses resulting from or associated with inflammation, and the like.
    Type: Application
    Filed: May 26, 2011
    Publication date: September 22, 2011
    Inventors: Lucie Szucova, Marek Zatloukal, Lukas Spichal, Jiri Voller, Karel Dolezal, Miroslav Strnad, Frank J. Massino